PLX4032: does it keep its promise for metastatic melanoma treatment?
Authors:
- Lisa ZimmerLZLisa Zimmer
- Sarah PielSPSarah Piel
- Dirk SchadendorfDSDirk Schadendorf
- 14 October 2010
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 19 (11) , 1439-1449
Abstract
Importance of the field: Activating mutations in the BRAF kinase gene have been identified in 50% of all melanomas. PLX4032, a selective and potent inhibitor of BRAF V600E mutant tumor cells, has shown inhibition of tumor growth in cell lines harboring BRAF V600E mutations. Data from early clinical trials showed promising results in the treatment of patients with metastatic melanoma. Areas covered in this review: An extensive literature search was conducted that included published articles and abstracts on PLX4032 to evaluate the existing data in both preclinical and Phase I–II studies. What the reader will gain: The review comprises the rationale for choosing a selective BRAF inhibitor for certain types of melanoma, its mode of action, associated toxicities and potential pitfalls. Take home message: Despite the convincing response rates in Phase I trials, duration of tumor response is limited in some patients, and a cure cannot be expected. Intrinsic and acquired PLX4032 resistance still has to be invest...Keywords
This publication has 50 references indexed in Scilit:
- Final Version of 2009 AJCC Melanoma Staging and ClassificationJournal of Clinical Oncology, 2009
- Increasing Burden of Melanoma in the United StatesJournal of Investigative Dermatology, 2009
- MelanomaJournal of the National Comprehensive Cancer Network, 2009
- Short German guidelines: Malignant melanomaJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2008
- Management of Metastatic MelanomaSeminars in Oncology, 2007
- Systemic therapy of disseminated malignant melanoma: an evidence‐based overview of the state‐of‐the‐art in daily routineJournal of the European Academy of Dermatology and Venereology, 2007
- Distinct Sets of Genetic Alterations in MelanomaNew England Journal of Medicine, 2005
- The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanomaFrontiers in Bioscience-Landmark, 2005
- Management of Cutaneous MelanomaNew England Journal of Medicine, 2004
- UK guidelines for the management of cutaneous melanomaBritish Journal of Plastic Surgery, 2002